773059-20-4Relevant academic research and scientific papers
POLYMORPH OF RUCAPARIB MESYLATE
-
Page/Page column 15, (2021/08/14)
The present invention relates to an anhydrous crystalline form of rucaparib mesylate, preferably in polymorphically pure form and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the anhydrous
CRYSTALLINE SALT OF A TRICYCLIC POLY(ADP-RIBOSE) POLYMERASE INHIBITOR
-
Page/Page column 17, (2019/05/22)
The present invention relates to crystalline rucaparib mesylate salt and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the crystalline rucaparib mesylate salt and at least one pharmaceutica
SALTS OF TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES
-
Page 10, (2008/06/13)
Pharmaceutically acceptable salts of compounds of the formula (I) below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegener
